DIA: Driving Insights to Action
Science:Life Sciences
As Johnson & Johnson Chief Medical Officer, DIA 2019 Co-Chair Dr. Joanne Waldstreicher is responsible for the company’s collaborations in ethical science, technology, and R&D policies, including those related to clinical trial transparency and compassionate access. “When you ask people why they’re participating in a clinical trial, a big part of it is to benefit themselves, they might have a condition or a disease where they’re looking for a new treatment option,” she explains. “But a very large part of their motivation is to contribute to medical knowledge that will advance or help care for a future patient.”
Need for Value Creates Opportunity for Patients
Can Europe Optimize Healthcare Quality AND Pricing?
Rules for Successful Patient-Industry Engagement
Multiple Channels Can Share “One Medical Voice”
Advertising & Promotion: What You Can (and Can’t) Say
Could Precision Medicine Deliver “You on a Chip”?
“Enlightened Regulation” Illuminating Translational Science
Time and Place for Innovation in a Pandemic Outbreak?
SFDA Talks Drug Pricing & Shortages in Advance of MERC 2017
Translating Medical Information into Effective Communication
Tufts eClinical Study: Complexity Overrunning Technology
Post-Brexit PV in Europe “An Issue We Shouldn’t Underestimate”
CDER Director: Interest in How Patients Feel & Function
EU Clinical Trial Regulation Streamlines to "Matter of One"
The Gaps In Drug Pricing
Biosimilars’ Good News for Patients
Pace of Innovation vs. Regulation: Combination Challenge
Oligonucleotides Driving Personalized Medicine Research
Celebrating 150 Years with Better Care for Canadians
Future Science & Drug Review: FDA Closing the Gap
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Terrace | تراس